Job Trends
Graphite Bio is discontinuing the development of nulabeglogene autogedtemcel (nula-cel), its lead asset, and shaving off about 50% of its workforce.
Labor Market Reports
The life sciences job market continues to shift. BioSpace’s Q2 2025 U.S. Life Sciences Job Market Report is now available, offering exclusive insights into the latest hiring trends, layoffs, and workforce dynamics across the life sciences industry.
Year-over-year BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities during the first quarter of 2025.
The 9% average salary increase from 2023 to 2024 was the largest for life sciences professionals since 2021. Several factors could be behind the spike, including companies providing higher pay because bonuses and stock compensation went down.
Now Hiring
Looking for a biopharma job in North Carolina? Check out the BioSpace list of seven companies hiring life sciences professionals like you.
Looking for a biopharma job in California? Check out the BioSpace list of 11 companies hiring life sciences professionals like you.
Looking for a biopharma job in Illinois? Check out the BioSpace list of six companies hiring life sciences professionals like you.
Career Advice
Most people avoid networking connections due to uncomfortable situations. In contrast, strategic networking can be extremely beneficial for your career.
THE LATEST
Novartis managed to bridge the gap between evidence of efficacy and value in this space with a variety of value-based pricing plans developed with regional payers.
Eli Lilly is jumping into the RIPK1 chase, paying $125 million up front to partner with Rigel Pharmaceuticals to co-develop its lead RIPK1 inhibitor program across all indications.
In 2020, Vir and GlaxoSmithKline partnered to develop strategies against COVID-19. The two companies have expanded that collaboration to include work into new treatments for influenza and other respiratory viruses.
The companies have announced their intent to appeal the decision.
AstraZeneca Chief Executive Officer Pascal Soriot is seeing a significant return on the fruits of his company’s labor in 2020. Soriot’s annual compensation jumped a bit from the previous year to $21.4 million.
Josh Smiley’s termination from Eli Lilly for inappropriate communications with employees will cost more than a blow to his reputation.
Under the terms of the deal, Sandoz is paying GSK $350 million at closing and additional milestones up to $150 million.
The company’s head of drug development, Samit Hirawat, told analysts in a conference call last week that the decision was about working with the best drugs, particularly in a crowded field like BCMA.
In the waning weeks of the fourth quarter of the 2020 fiscal year, AstraZeneca terminated several clinical programs, including some oncology and heart-related studies, as well as one COVID-19 related trial.
AbbVie committed up to another $300 in potential milestone payments.